[1] FRIEDMAN S L，ROCKEY D C，BISSELL D M.Hepati fibrosis 2006： Report of the third AASLD single tropic research conference[J] .Hepotlolgy，2007，45(1)：242-249. [2] GRESSNER A M，WEISKIRCHEN R.Modern pathogenetic concepts of liver fibrosis suggest stellate cell and TGFβ1 as major player and therapeutic targets[J] .J Cell Mol Med，2006，10(1)：76-99. [3] FRIEDMAN S L，BANSAL M B.Reversal of hepatic fibrosis-fact or fantasy[J] .Hepatslogy，2006，43(Suppl 2)：82-88. [4] ALBANIS E，FRIEDMASN S L.Antifibrotic agents of liver disease[J] .Am J Transpl，2006，6(1)：12-19. [5] CAI W M.Some reseach progression of hepatic fibrosis[J] .Chin J Chini Hepatol（临床肝胆病杂志），2006，2（3）：167-170 [6] MUHANNA N，AZZEH M，DORON S，et al.Immune modulator anti-fibrottic activity of SIRNAS in liver diseases[J] .Hepatology，2006，44(4，suppl 1)：263. [7] MCAVOY E F，KUBES P.Holey entothelium： Gate ways for na ve T cell activatin[J] .Hepatology，2006，44(5)：1083-1085. [8] CHEN C H，KUO L M，CHANG Y，et al.In vivo immune madulatory of hepatic stellate cells in mice[J] .Hepatology，2006，44(5)：1171-1181. [9] PERRILLO R P，GISH R G，PETERS M，et al.Chronic hepatitis B： a critical appraisal of current approaches to therapy[J] .Clin Gatroenterol Hepatol，2006，4：233-248. [10] KEEFFE E B，DIETERICH D F，HAN S B，et al.Treatment algorithm for the management of chronic hepatitis B virus infection in the United state： An Update[J] .Clin Gastroenterol Hepatol，2006，4：936-962. [11] WASMUTH H E，TRAUTWEIN C.CB1 Cannabinoid receptor antagonism; A new strategy for the treatment of liver fibrosis[J] . Hepatology，2007，45(2)：543-544. [12] WEN H L，CAI W M，WANG B E，et al. Clinical study of anti-hepatic fibrosis effect of IFN-γ in patients with chronic hepatitis B[J] .Natl Med J China(中华医学杂志)，2003，83(11)：943-947. [13] WENG H L，WANG B E，JIA J D，et al. Effect of IFN-γ on hepatic fibrosis in chronic hepatitis B virus infection： A randomized controlled study[J] .Clin Gastroenterol Hepatol，2005，3(8)：819-828. [14] PROCKROS P，JEFFERS L，AFDHAL N，et al.Final results of A double-blind，placebo-controlled trial of the antifibrotic efficacy of interferon-rlb in chronic hepatitis C patients with advanced fibrosis or cirrhosis[J] .Hepatology，2007，45(1)：569-578. [15] LI Q，ZHANG Y J，SHI G F，et al. A multicenter clinical study of anfate for treatment of hepatic fibrosis in patients with chronic liver disease[J] .Chin J Hepatol（中华肝脏病杂志），2007；15（10）：749-752. [16] CALDWELL S H，ARGO C K.Divergent effects of peroxisome proliferators-activated receptor-γ ligands in human and mouse nonalcoholic steatohepatitis[J] .Hepatology，2007，46(2)：285-287. [17] LIVER O C. Chinese association of integrative medicine.Guidelines for the diagnosis and treatment of liver fibrosis in integrative medicine practive[J] .Chin J Hepatol（中华肝脏病杂志），2006，14(11)：866-870. [18] WU C H，SI C W，TIAN G S，et al. An analysis of the pathohistology of liver tissues of the pathohistology of liver tissues, clinical features and prognostic factors of chronic hepatitis B virus carriers.[J] .Chin J Hepatol(中华肝病杂志)，2007，15(8)：577-581.